Boston Scientific Reports 17.4% Growth in Neuromodulation Revenue for Q1 2026
Summary
Boston Scientific announced first quarter 2026 financial results showing neuromodulation revenue of $318 million, representing 17.4% growth on a reported basis compared to the prior year period. The company's neuromodulation portfolio includes spinal cord stimulation, deep brain stimulation, and sacral neuromodulation therapies for chronic pain, movement disorders, and pelvic floor dysfunction.
Why it matters
The strong growth in Boston Scientific's neuromodulation business reflects continued market expansion and adoption of neurostimulation therapies across multiple clinical indications. As one of the largest medical device companies, Boston Scientific's neuromodulation performance signals broader industry health and investment in next-generation neurostimulation technologies. The growth may be driven by new product launches, expanded indications, and increased physician adoption of neuromodulation therapies.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial